BeOne Medicines (688235.SS) Earnings Analysis
BeOne Medicines (688235.SS) has no confirmed upcoming earnings date. Last quarter (2026-02-26) it missed with EPS 0.3301 CNY vs 0.671 CNY est (-50.8%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E 5.01.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 688235.SS next report earnings?
No confirmed upcoming earnings date is currently scheduled for 688235.SS. This page updates as the calendar is published.
688235.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-26 | 0.3301 CNY | 0.671 CNY | -50.8% | Miss |
| 2025-11-06 | 0.647 CNY | 0.54 CNY | +19.8% | Beat |
| 2025-02-24 | -0.86432 CNY | -0.61152 CNY | -41.3% | Miss |
Beat rate: 1/3 (33%) over reported quarters with consensus data.
688235.SS valuation and analyst view
| Trailing P/E | 5.01 |
|---|---|
| Trailing EPS | 0.35725 CNY |
| Price / book | 12.15 |
| Dividend yield | 0.00% |
| Market cap | 289.97B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is BeOne Medicines (688235.SS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 688235.SS. This page updates as the calendar is published.
Did 688235.SS beat earnings last quarter?
In its 2026-02-26 report, 688235.SS posted EPS of 0.3301 CNY versus a 0.671 CNY estimate — a miss of 50.8%.
What is 688235.SS's earnings track record?
Over the last 3 reported quarters with consensus data, 688235.SS beat estimates 1 times (33%).
What is 688235.SS's current P/E ratio and EPS?
688235.SS trades at a trailing P/E of 5.01 on trailing EPS of 0.3572488515682676 CNY.
What do analysts rate 688235.SS?
688235.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.